Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-04991532, a Hepatoselective Glucokinase Activator (GKA), Administered as Monotherapy in Japanese and Non-Japanese T2DM Patients

被引：0

作者：

Kazierad, David

Bergman, Arthur

Pfefferkorn, Jeffrey A.

Wang, Xin

Rolph, Timothy

Rusnak, James M.

机构：

来源：

DIABETES | 2013年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1108-P

引用

页码：A287 / A288

页数：2

共 25 条

[21] Evaluation of GSK1292263, a Novel GPR119 Agonist, in Type 2 Diabetes Mellitus (T2DM): Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses
Nunez, Derek J.
Bush, Mark A.
Collins, David A.
Mcmullen, Susan L.
Feldman, Paul L.
Jackson, Tymissha D.
Ross, Sean A.
DIABETES, 2011, 60 : A273 - A273
[22] DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase lb Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)
Kim, Mi-Kyung
Lee, Dae Young
Jeong, Jiyoon
Grimm, Michael
Franey, Bridgette B.
Hompesch, Marcus
DIABETES, 2021, 70
[23] Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-blind randomized study of ipragliflozin to show its efficacy as monotherapy in T2DM patients
Kashiwagi A.
Kazuta K.
Takinami Y.
Yoshida S.
Utsuno A.
Nagase I.
Diabetology International, 2015, 6 (1) : 8 - 18
[24] Sitagliptin, a DPP-4 inhibitor, administered once- or twice-daily, provides substantial improvement in 24-hour glucose control in Japanese patients with type 2 diabetes mellitus (T2DM)
Nonaka, Kenji
Tsubouchi, Hiroshi
Okuyama, Kotoba
Fukao, Yukako
Stein, Peter P.
DIABETES, 2007, 56 : A540 - A540
[25] PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) ANALYSIS OF TRASTUZUMAB EMTANSINE (T-DM1) IN JAPANESE PATIENTS WITH ADVANCED OR RECURRENT HER2-POSITIVE BREAST CANCER (JO22591): COMPARISON WITH WESTERN PATIENTS.
Igawa, Y.
Matsubara, M.
Matsunaga, K.
Aogi, K.
Fujiwara, Y.
Iwata, H.
Girish, S.
Olsen, S.
Yi, J.
Saad, O.
Gupta, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S65 - S66

← 1 2 3 →